Carrick Therapeutics
PrivateLast Round
Series C
Dec 1, 2022
Total Funding Raised
$222M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Carrick Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series C round in December 2022.
Carrick Therapeutics is a biotechnology company that develops innovative cancer therapeutics targeting molecular pathways to improve treatment outcomes for patients with aggressive and resistant forms of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Carrick Therapeutics Comparables
Compare Carrick Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Syros Pharmaceuticals Inc | 82% | |
| Avenzo Therapeutics | 79% | |
| Incyclix Bio | 79% |
For institutional investors. Book with your work email.
Carrick Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 1, 2022 | ||||
| Convertible Debt | Aug 1, 2021 | ||||
| Series B | Nov 14, 2019 | ||||
| Series A | Oct 3, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Carrick Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EQT Life Sciences | Series B |
| SV Health Investors | Series A |
| GV | Series A, Series B, Series C |
| Cambridge Enterprise Ventures | Series A |
| Lightstone Ventures | Series B, Series C, Series A |
| Woodford Investment Management | Series B, Series A |
| ARCH Venture Partners | Series B, Series C, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 69% MoM, reaching 2.4K.
- Apr 20, 2026
Monthly visitors grew 249% MoM, reaching 2.5K.
For institutional investors. Book with your work email.
Carrick Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Carrick Therapeutics's valuation, stock price, and market status.
Is Carrick Therapeutics a public or private company?
Carrick Therapeutics is a private company.
What is the current stock price of Carrick Therapeutics?
Carrick Therapeutics is a private company, so its shares have no public market price. Caplight tracks Carrick Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Carrick Therapeutics worth (valuation)?
Valuation information for Carrick Therapeutics is not publicly available.
Can I buy Carrick Therapeutics stock?
Carrick Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Carrick Therapeutics's last funding round?
Carrick Therapeutics's most recent funding round was Series C on December 1, 2022.
Who are the main investors in Carrick Therapeutics?
Key investors in Carrick Therapeutics include EQT Life Sciences, SV Health Investors, Woodford Investment Management, ARCH Venture Partners, Pfizer.
Will Carrick Therapeutics IPO soon?
No public IPO plans have been announced for Carrick Therapeutics.
How can I track Carrick Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Carrick Therapeutics's shares on secondary markets.